|
|
||||||||
Ann Thorac Surg 2005;80:642-646
© 2005 The Society of Thoracic Surgeons
Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of Medicine, and Childrens Healthcare of Atlanta at Egleston, Atlanta, Georgia
Accepted for publication February 14, 2005.
* Address reprint requests to Dr Kanter, Division of Cardiothoracic Surgery, Emory University School of Medicine, 1365 Clifton Road, Atlanta, GA 30322 (Email: kkanter{at}emory.edu).
Presented at the Fifty-first Annual Meeting of the Southern Thoracic Surgical Association, Cancun, Mexico, Nov 46, 2004.
| Abstract |
|---|
|
|
|---|
METHODS: Of 82 MVRs at our institution since 1988, 22 were redo MVRs in 21 children aged 1.421 years (mean 9.8 ± 5.6 years). Interval from initial MVR was 1 month to 18 years (mean 5.8 ± 4.9 years). Reoperation indication was primarily stenosis in 13 (usually pannus formation), regurgitation in 4, valve thrombosis or embolism in 4, and endocarditis in 1. The initial valve was mechanical in 18 and xenograft in 4.
RESULTS: During redo MVR, 8 of 22 (36%) patients had additional procedures including left ventricular outflow tract obstruction relief or aortic valve replacement in 4 and tricuspid valve repair in 2. The new mitral valve was mechanical in 20 and xenograft in 2. Median valve size increased from 21 mm to 25 mm although 7 valves were not upsized on rereplacement (average valve size increase was 3.3 ± 1 mm). Only 2 patients (9%) needed a new pacemaker. There were no hospital deaths. Six children developed end-stage heart failure and underwent successful cardiac transplantation 3 to 32 (mean 12.1 ± 10.0) months, postoperatively. On follow-up of 1 month to 7.7 years (mean 2.5 ± 2.3 years) there has been only one late death of an unrecognized coronary artery anomaly.
CONCLUSIONS: Redo MVR in children can be performed safely with low morbidity and mortality. A larger prosthesis can often be placed in these children. A surprisingly high percentage of patients eventually require transplantation, perhaps reflecting unnecessary delay in referral for redo MVR.
| Introduction |
|---|
|
|
|---|
| Patients and Methods |
|---|
|
|
|---|
|
| Results |
|---|
|
|
|---|
|
Fifteen of the 22 redo mitral valves were larger in size than the original MVR (Fig 1 ). The median valve size of the original valve replacement was 21 mm and size of the redo MVR was 25 mm for an average valve size increase of 3.3 ± 3.1 mm. Seven valves that did not have an increase in size at the time of redo MVR. In four instances, this was due to redo valve replacement within a year of the initial operation. For two of the other three instances, the original valve was 31 mm in size as was the new mitral valve.
|
All patients survived hospitalization in this series. On follow-up from one month to 7.7 years (mean 2.5 ± 2.3 years), there was one late death in a patient with an unsuspected coronary artery anomaly. This was the patient who had unexplained syncope with rare episodes of second-degree heart block for which a pacemaker had been placed after hospital discharge from her redo MVR. Six patients developed severe heart failure and underwent successful cardiac transplantation between 2.5 months and two and one-half years after redo MVR (mean 12.1 ± 10.2 months). All patients had a normally functioning prosthetic heart valve at the time of transplantation.
| Comment |
|---|
|
|
|---|
Even after the first report of a redo MVR in a child by Robinson and Young in 1966 [10], there was concern that this reoperation would carry a high operative morbidity and mortality. It was felt that once the mitral valve annulus was "fixed" by the prosthetic valve sewing ring with initial placement of the valve, subsequent valve rereplacements would mandate the placement of a small prosthesis since, in growing children, there are no easily applied surgical techniques for enlarging the mitral annulus as there are for the aortic annulus. Most reports on this topic have been single institution series with low numbers (10 or fewer) of patients [2, 57, 1116]. Although all of these series are small, in general, the mortality rates with redo MVR have been low. Furthermore, many of these series showed the feasibility of increasing the prosthetic valve size with redo MVR.
There have, however, been two single institution studies with relatively large numbers of MVRs. A report by Antunes [1] from Johannesburg, South Africa, reported 135 bioprosthetic MVRs in children, of which 62 were redo MVRs. There was a 17.2% early mortality with redo MVR. This series, however, consisted mostly of older children (mean age 13.7 years) operated on for rheumatic heart disease. Since the initial MVR was uniformly a bioprosthetic valve, the reoperation rate was high. The high operative mortality was attributed to delayed reoperation in that many of their patients underwent urgent or emergent reoperation. Alternatively, this high early mortality could be impacted by underlying myocardial dysfunction secondary to long standing valve disease or rheumatic heart disease.
A more recent study from Arkansas Childrens Hospital [17] reported 23 redo MVRs in 18 patients with no early deaths, but with three late deaths and five transplants. A multiinstitutional study [8, 18] from the Pediatric Cardiac Care Symposium reported on 32 redo MVRs with two early deaths and two late deaths.
The current series demonstrates that redo MVR can be done quite safely since there were no operative deaths in this series. In the early days of valve surgery, it was feared that placing a fixed sewing ring in the mitral annulus of a child would consign that child to a fixed annulus so that subsequent valve replacements would always be of similar size. We were able to upsize the redo mitral valve prosthesis in 15 of our 22 reoperations (Fig 1) with a median valve size increase from 21 mm to 25 mm. Despite increasing the valve size, only two patients in this series developed new onset of complete atrioventricular block requiring a pacemaker. The ability to increase the size of the mitral valve prosthesis at the time of rereplacement has been observed by others in smaller series [5, 6, 1215, 17, 18].
Of concern is the fact that six of our 21 patients required cardiac transplantation within two and one half years of redo MVR. Two of these patients had cardiomyopathy before their MVR and the valve was replaced in hopes of delaying transplantation. The remaining four, however, appeared to be suffering from the ravages of ongoing valvular congenital heart disease. Eble and colleagues [17] from the Arkansas Childrens Hospital also found a high incidence of children requiring transplantation after redo MVR. Van Doorn and colleagues [6] from Great Ormond Street in London have shown that 41% of children after MVR have echocardiographic wall motion abnormalities, which certainly can contribute to ventricular dysfunction. It is difficult to determine the etiology of this abnormality, although there are several possible explanations. One is the deleterious effects of removing the tensor apparatus with the subvalvular tissue as is commonly necessary in pediatric MVR in order to place a larger prosthesis. Secondly, many of these children have underlying congenital heart disease with long standing heart failure or other lesions as is seen with Shones syndrome. A third explanation is abnormal conduction patterns in patients who have pacemakers after MVR, which can diminish ventricular function. Of interest is our one patient who required emergency MVR three weeks after repair of anomalous origin of the left coronary artery from the pulmonary trunk. This child had persistent left ventricular dysfunction after the coronary artery repair so it was elected to place a porcine valve at that time because of the childs poor prognosis and poor ventricular function. However, at the time of redo MVR nine months later for bioprosthetic valve regurgitation, a biventricular pacemaker system was placed prophylactically in order to achieve electrical resynchronization. After this childs redo MVR, her left ventricular ejection fraction over the course of four months has increased from 35% to 69% by echocardiography.
The possibility, of course, exists that these children are referred for reoperation too late in their course. Understandably, there is reluctance to refer these patients for repeat mitral valve replacement for a variety of reasons. One thought is that the operative risk is too high; certainly this argument has been dispelled with our current results. A second possibility is that in an effort to place a larger, more appropriate valve size in a growing child, the risk of new onset heart block is worrisome. Again, since this occurred in only nine percent of our series, this concern too, has been lessened.
In summary, we feel that redo mitral valve replacement in children can be performed safely. In general, a larger prosthetic valve can be placed. There remains the concern for ongoing heart failure leading to transplantation. For these reasons, we recommend earlier referral for redo mitral valve replacement.
| Discussion |
|---|
|
|
|---|
Did you perform an actuarial survival of your patient population? Im not sure about the estimation, but it seems to me that it is 60% 5-year survival or maybe 70% 5-year or 10-year survival. And if that is the case, and it probably is, I think your point about early referral, and also referral for cardiac transplantation, is a good one.
I would mildly disagree with your comment that this situation is alarming. I think this mode of therapy is to be expected. Proceeding with transplantation in selected cases gives these patients a better outlook, especially when ventricular dysfunction is unlikely to improve after a valve reoperation. I wonder if you can comment on this issue.
DR KANTER: Well, Gus, it is hard to develop an actuarial survival when we only had one death in the whole series. Now, if you look at failure, including transplant, then we could have constructed that graph. We previously have reported our entire mitral valve replacement series, and the actuarial survival at about 5 years is similar to that of other series, and you are right, it is in the 60 to 70% range. Placing the mitral valve in a child is not a benign process and the long-term outlook is not really terrific.
DR JOHN H. CALHOON (San Antonio, TX): Kirk, I very much enjoyed your presentation, thought it was well illustrated and well done. Could you describe a little bit, I have done a few redo mitral valves, how are you able to upsize them, where do you find the room, please?
DR KANTER: As all of us in the audience are aware, there are no good techniques applicable to the mitral valve annulus as there are for the aortic annulus like a Manougian or a Nicks or a Konno procedure. However, when we remove the prosthetic mitral valve, we are very careful to debride the annulus and to remove all the prosthetic material and fibrotic tissue. With that, without really making any extra incisions, we are surprised that that really increases the annulus, which is counterintuitive. I think that that in the past has been the reluctance to reoperate on these children because you feel that you are just going to be able to put in the same size valve. But as we have shown, without really doing anything special other than debriding the annulus and taking out all the scar tissue and prosthetic tissue, we are generally able to upsize from a median valve size of 21 to a median of 25.
DR D. GLENN PENNINGTON (Johnson City, TN): There were several patients who required replacement within a year or so. I wondered if you have had any experience with fibrinolytic treatment of these valves, particularly the mechanical valves, I guess the question would be, is that a worthwhile thing to do in this population?
DR KANTER: We actually reported a case series of three patients in the Journal of Thoracic and Cardiovascular Surgery that were successfully managed with thrombolytic therapy within the first few days of recognition of valve thrombosis. The few cases in our series that were replaced soon after implantation included one patient with endocarditis. There was one patient with that Silzone-impregnated St Jude valve that went in beautifully and had no leak. Four months later he had regurgitation. That particular valve has been withdrawn from the market for this problem with early regurgitation.
One disturbing patient was a small child where we put a St Jude valve in the supraannular position. About five months after implantation, one of the leaflets got stuck, and we took him back, replacing it with another St Jude valve. It worked great in the operating room. A month later it got stuck again, and we tried thrombolytic therapy, which worked for a week and then it got stuck again. We felt that in the supraannular position there was something about the morphology of her atrium that was catching the leaflet. We, therefore, put a bioprosthetic valve in her, and that has been a year now. So that pretty much accounts for the short interval redo replacements.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. W. Brown, A. C. Fiore, M. Ruzmetov, O. Eltayeb, M. D. Rodefeld, and M. W. Turrentine Evolution of Mitral Valve Replacement in Children: A 40-Year Experience Ann. Thorac. Surg., February 1, 2012; 93(2): 626 - 633. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Kanter, B. E. Kogon, and P. M. Kirshbom Supra-Annular Mitral Valve Replacement in Children Ann. Thorac. Surg., December 1, 2011; 92(6): 2221 - 2229. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Alsoufi, C. Manlhiot, M. Al-Ahmadi, B. W. McCrindle, A. Kalloghlian, G. Siblini, Z. Bulbul, and Z. Al-Halees Outcomes and associated risk factors for mitral valve replacement in children Eur J Cardiothorac Surg, September 1, 2011; 40(3): 543 - 551. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Durham III, H. M. Burkhart, J. A. Dearani, F. J. Puga, P. W. O'Leary, and H. V. Schaff Mitral Annular Growth in Children Following Early Mechanical Mitral Valve Replacement World Journal for Pediatric and Congenital Heart Surgery, July 1, 2010; 1(2): 177 - 181. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Alsoufi, C. Manlhiot, B. W. McCrindle, Z. Al-Halees, A. Sallehuddin, S. Al-Oufi, E. Saad, B. Fadel, and C. C. Canver Results after mitral valve replacement with mechanical prostheses in young children J. Thorac. Cardiovasc. Surg., May 1, 2010; 139(5): 1189 - 1196. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ackermann, G. Balling, A. Eicken, T. Gunther, C. Schreiber, and J. Hess Replacement of the systemic atrioventricular valve with a mechanical prosthesis in children aged less than 6 years: Late clinical results of survival and subsequent replacement J. Thorac. Cardiovasc. Surg., September 1, 2007; 134(3): 750 - 756. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |